학술논문
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
Document Type
Article
Author
Zhou, Qing ; Yang, Nong ; Zhao, Mingfang ; Huang, Dingzhi ; Zhao, Jun ; Yu, Yan ; Yuan, Ying ; Sun, Longhua ; Dong, Xiaorong ; Zhang, Tongmei ; Chu, Qian ; Li, Xingya ; Meng, Xiangjiao ; Wang, Huijuan ; Wang, Xiang ; Wu, Dongde ; Hu, Sheng ; Shan, Jinlu ; Liu, Lian ; Sun, Meili ; Zhang, Zhiye ; Zhu, Haibo ; Huang, Jingjing ; Huang, Mengna ; Cheng, Lingge ; Zhang, Sujie ; Zhou, Hui ; Wu, Yi-Long
Source
In European Journal of Cancer November 2024 212
Subject
Language
ISSN
0959-8049
Abstract
@@@@Highlights •IBI351 was well tolerated in advanced solid tumor patients harboring KRAS G12C.•IBI351 demonstrated promising efficacy in advanced NSCLC patients with KRAS G12C.•IBI351 might be a novel treatment option for advanced solid tumors with KRAS G12C.